| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
-Validation Studies Confirmed the Assay Can Detect Mpox Clade I and Clade Ib in addition to Clade II-
STONY BROOK, NY / ACCESSWIRE / August 23, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State Department of Health (NYSDOH) in support of an expansion of the permitted use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include both mpox clade I and clade II. The Company's validation studies concluded that the Assay's primers and probe have 100% homology to mpox clade I and clade Ib, the latter of which was the subject of the World Health Organization's (WHO) recently declared public health emergency of international concern.
The timeline for NYSDOH's review of the Company's validation package is not currently known and there can be no assurances that NYSDOH will approve the Company's requested expansion of the Assay to clade I.
Posted In: APDN
